secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0000914475-26-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B
--------------------------------------------------------------------------------

- Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).
- INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.
- CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.
- GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).
- Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/0000914475-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/nbix-20260211.htm
  HTML page:      https://secwatch.observer/filing/0000914475-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer